drugset / Trial / NCT02740335

Study of Octaplex, a Four-factor Prothrombin Complex Concentrate (4F-PCC) and Beriplex® P/N (Kcentra) for the Reversal of Vitamin K Antagonist (VKA) Induced Anticoagulation in Patients Needing Urgent Surgery With Significant Bleeding Risk.

NCT02740335

Phase 3 Completed 208 enrolled Octapharma
RandomizedSingle-groupTriple-blindTreatment

Summary

To demonstrate that the efficacy of OCTAPLEX as a reversal agent in patients under Vitamin K Antagonist (VKA) therapy with the need for urgent surgery with significant bleeding risk is clinically non-inferior to that Beriplex® P/N (Kcentra).

Timeline

Start
2017-06-08
Primary completion
2022-02-23
Completion
2022-02-23

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Beriplex P/N (Kcentra) Unknown 25 iu/kg Intravenous
Comparator Beriplex P/N (Kcentra) Unknown 35 iu/kg Intravenous
Comparator Beriplex P/N (Kcentra) Unknown 50 iu/kg Intravenous
Subject Octaplex Protein / enzyme biologic 25 iu/kg Intravenous
Subject Octaplex Protein / enzyme biologic 35 iu/kg Intravenous
Subject Octaplex Protein / enzyme biologic 50 iu/kg Intravenous

Indications

No indication recorded.